Earlier this week, a batch of Silver-111 (Ag-111) arrived at the BIOEMTECH Laboratories for a collaborative research project! This radionuclide, with a half-life of 7.45 days, emits both beta and gamma radiation, making it a promising candidate for therapeutic and diagnostic applications.
Why is Ag-111 interesting?
- It can be used in targeted radionuclide therapy (TRT), particularly in oncology.
- Its gamma emissions, with energy peaks at 245 keV and 342 keV, enable SPECT imaging, allowing real-time tracking of therapeutic agents.
- With an average β-energy of 360 keV, it has a tissue penetration of around 1 mm.
- Produced by proton or neutron bombardment, it is a valuable tool in nuclear medicine research.
This study is performed in the framework of the ISOLPHARM project in collaboration with our long-lasting partner Mattia Asti, and as always, our labs are ready to explore the potential of this isotope. Stay tuned for more updates from our research journey!